Ident. | Authors (with country if any) | Title |
---|
001483 (2012) |
Dominic Nadeau [Canada] ; Isabelle Giroux [Canada] ; Julie Dufour [Canada] ; Martine Simard [Canada] | Jeu pathologique chez les patients atteints de la maladie de Parkinson |
001956 (2011) |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
002068 (2009) |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
002E27 (2003) |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study |
002E96 (2003) |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
002F05 (2003) |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
002F43 (2003) |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
002F45 (2003) |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
003049 (2002) |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
003053 (2002) |
J. Q. Lu [Canada] ; A. J. Stoessl [Canada] | Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats |
003054 (2002) |
H. Uri Saragovi [Canada] ; Maria Clara Zaccaro [Canada] | Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites |
003058 (2002) |
Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
003092 (2002) |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
003103 (2002) |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
003159 (2001) |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study |
003305 (2001) |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
003310 (2001) |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
003332 (2001) |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
003352 (2001) |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
003354 (2001) |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
003557 (2000) |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |